Advertisement

Topics

Latest Biological Patent NewsRSS

03:10 EDT 30th April 2017 | BioPortfolio

Doudna and Charpentier and their teams to receive wide-ranging patents in many countries: European Patent Office (EPO) and UK Intellectual Property Office – broad patent for CRISPR-Cas9 gene-editing technology to the University of California and the Un

Doudna and Charpentierand their teams to receive wide-ranging patents in many countries:  European Patent Office (EPO) and UK Intellectual Property Office – broad patent for CRISPR-Cas9 gene-editing technology to the University of California and the University of Vienna Reporter: Aviva Lev-Ari, PhD, RN   The EPO patent will cover the single-guide CRISPR-Cas9 technology in cells of [&#...

Thermi Continues to Defend against Viveve’s Patent Infringement Lawsuit

A recent District Court decision supports Thermi's position that physicians using ThermiVa® to treat patients will not be liable for infringement ThermiGen’s portfolio, is based on the ‘Science of Heat’ radiofrequency technology Almirall, S.A., the global pharmaceutical company based in Barcelona, wil...

STAT Plus: US trade rep’s watch list gives consumer groups one pleasant surprise

Is the Trump administration siding with consumer groups over drug makers in the fight over patient access and patent rights? The US trade representative on Friday released its annual 301…

CEL-SCI Receives Intent to Grant Notice for New Multikine Patent from the European Patent Office

CEL-SCI Corporation (NYSE MKT: CVM) today announced that it has been notified that it will be granted a new patent on Multikine* (Leukocyte Interleukin, Injection), its investigational cancer immunotherapy, from the European Patent Office. The patent is titled: A METHOD FOR MODULATING HLA CLASS II TUMOR CELL SURFACE EXPRESS

Does plant patent system restrict innovation and hurt small breeders?

Patent challenges hit Actavis and Acorda

Teva Pharmaceuticals’ subsidiary Actavis and neurological drug specialist Acorda Therapeutics have both faced patent challenges recently over treatments for acne and multiple sclerosis, respectively. 

CEL-SCI Receives Intent To Grant Notice For New Multikine Patent From

  Life Sciences Jobs   ...

SpinalCyte, LLC Receives New Australian Patent

SpinalCyte, LLC, a Texas-based tissue engineering technology company focused on regrowth of the spinal disc nucleus using human dermal fibroblasts, announced today the issuance of Australian Patent No. 2013299505, “Generation Of Cartilage Ex Vivo From Fibroblasts.” The technology described in the patent involves using mechanical stress ...

Providence Medical Technology Announces Issuance of Four Additional U.S. Patents

WALNUT CREEK, Calif., April 27, 2017 /PRNewswire/ -- Providence Medical Technology, Inc., an innovator in tissue-sparing cervical spine technology, today announced the U.S. Patent Office's issuance of four additional patents, Nos. 9,622,873; 9,622,791; 9,622,874; and 9,629,665, covering various aspects of its proprietary DTRAX® and CAVUX® posterior cervical spinal fixation technologies. ...

STAT Plus: Strap on your parachutes, pharma faces a mini patent cliff

Over the next three years, 40 branded drugs sold by nine large drug makers — totaling $60 billion in sales — are likely to encounter generic competition.

ArQule Announces Issuance of U.S. Patent Covering Composition of Matter of Proprietary Reversible BTK Inhibitor, ARQ 531

ArQule, Inc. (Nasdaq: ARQL) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number 9,630,968. The patent claims composition of matter of ARQ 531. ArQule will be entitled to patent protection through December 2035 in the U.S. for the allowed claims. ARQ 531 is an investigational, orally bioavailable, potent and reversible in...

MPP to make hep C drug affordable for low and middle income countries

Pharco Pharmaceuticals has granted a license to make, sell and export the hepatitis C drug ravidasvir (RAV) to Medicines Patent Pool (MPP). 

Aesthetic Medical Market News: RepliCel (OTCQB: $REPCF) (TSXV: $RP) Reports US Patent Issued for Novel Dermal Injection Technologies

VANCOUVER, BC - April 26, 2017 (Investorideas.com Newswire) Aesthetic Medical Market News alert ; RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a clinical stage regenerative medicine company developing cell therapies for aesthetic and orthopedic conditions, today announced the granting of a key patent in the United States (U.S. Patent No. 9,616,182) ...

Allergan Successfully Invalidates Claims Relating to Using Botox to Treat Back Pain

Allergan is typically the patent holder in these types of disputes, however, it recently successfully played the role of petitioner in an IPR against 1474791 Ontario Ltd.'s U.S. Patent No. 6,806,251 covering the use of botulinum toxin to treat spinal compression.

Aclaris Therapeutics Announces Notice of Allowance for a U.S. Patent Application Covering Lead Candidate A-101 Topical Solution

MALVERN, Penn., April 26, 2017 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led, biotechnology company focused on defining innovative therapies in medical and aesthetic dermatology, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering the formulation and methods ...

Intellia Therapeutics and CRISPR Therapeutics Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes

CAMBRIDGE, Mass. and BASEL, Switzerland, April 26, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) and CRISPR Therapeutics AG (NASDAQ:CRSP), two leading genome editing companies focused on the development of potentially curative therapies, announced that the United States Patent and Trademarks Office (“USPTO”) is expected to  issue a CRISPR/Cas9 genome editing patent t...

Titan Medical Issued U.S. Patent Related to SPORT Surgical System Robotic Instruments

TORONTO, ON--(Marketwired - April 26, 2017) - Titan Medical Inc. (TSX: TMD) (OTCQX: TITXF), a medical device company focused on the design, development and commercialization of a robotic surgical system for application in minimally invasive surgery (MIS), announces the issuance of U.S. Patent No. 9,629,688 titled "Actuator and Drive for Manipulating a Tool," which covers the Company's unique robot...

Intellia And CRISPR Announce U.S. Patent Covering CRISPR/Cas9 Ribonucleoprotein Complexes

  Life Sciences Jobs   ...

Aclaris Announces Notice Of Allowance For A U.S. Patent Application Covering Lead Candidate A-101 Topical Solution

  Life Sciences Jobs   ...

MPEG LA Invites CRISPR-Cas9 Patents to be Pooled in a One-Stop License

Accessibility to a multi-user market will maximize CRISPR’s life-enhancing potential World licensing leader MPEG LA, LLC today invited holders of CRISPR-Cas9 patents to participate in the creation of a global CRISPR-Cas9 Joint Licensing Platform that will make their groundbreaking technologies widely accessible. “Pooling the foundat...

Mati Therapeutics Hits Major Milestone with 100 Patents

Portfolio Covers 17 Patent Families Across Major Markets Mati Therapeutics, Inc. (“Mati”) announced that its international patent portfolio now comprises 100 issued patents. Included in the portfolio is recently granted U.S. Patent No. 9,610,271 titled, “Sustained release delivery of active agents to treat glaucoma and ocular

BeneVir Granted Patent Protecting Lead Oncolytic Immunotherapy Stealth-1H and Other Platform Assets

BeneVir Biopharm, Inc., a biotechnology company developing oncolytic immunotherapies for the treatment of cancer, announced today that the U.S. Patent and Trademark Office has issued US Patent No. 9,623,059, entitled “Oncolytic Herpes Simplex Virus and Therapeutic Uses Thereof”, covering the composition of matter for Stealth-1H, BeneVir’s lead oncoly...

Asuragen Strengthens Repetitive Sequence and Short Structural Variant Intellectual Property Portfolio

Asuragen, Inc., a global molecular diagnostics company, announced today the award of a patent (EP 2,411,532 B1) from the European Patent Office for PCR methods that analyze the presence of an interrupter sequence in CGG-rich regions of the fragile X mental retardation (FMR1) gene. This latest patent further strengt

Breaking RepliCel (OTCQB: $REPCF) (TSXV: $RP) @RepliCel News; US Patent Issued to for its Novel Dermal Injection Technologies

VANCOUVER, BC - April 25, 2017 (Investorideas.com Newswire) RepliCel Life Sciences Inc. (OTCQB:REPCF) (TSXV:RP) (FRA:P6P2) ("RepliCel" or the "Company"), a clinical stage regenerative medicine company developing cell therapies for aesthetic and orthopedic conditions, today announced the granting of a key patent in the United States (U.S. Patent No. 9,616,182) covering significant components of the...

Benevir Biopharm Granted Patent Protecting Lead Oncolytic Immunotherapy Stealth-1H And Other Platform Assets

  Life Sciences Jobs   ...

Quick Search
Advertisement
 

review and buy Biological Patent market research data and corporate reports here